Mechanistically, mTORC1 inhibits the transcription of SIRT4 by degrading its activator CREB2 (cyclic adenosine monophosphate responsive element-binding 2), thereby activating GDH [74,93,94]
The brain relies heavily on continuous ATP production
Patients in large clinical trials for GLP-1s lost an average of 15% to 20% of their body weight, depending on the drug they were given
Artahs Metabolic Fix, for example, includes compounds like berberine and L-carnitine, known for their metabolic benefits, but again, the evidence largely stems from studies on the ingredients rather than the product as a whole. Daniel OShaughnessy, a certified functional nutritionist agrees: These products are not groundbreaking, in fact, their ingredients have been used for years and years
Whilst emerging evidence suggests the extensive therapeutic potential of GLP-1, further studies are needed to fully elucidate its mechanisms and its clinical applications in gastrointestinal disorders
